innovative therapeutic approach of some devasting respiratory and cardiac diseases via MFALCs targetting

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K07420
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 49030:Experimental pathology-related
• Research Institution: Hokkaido University
• Principal Investigator: Elewa Yaser 北海道大学, 獣医学研究院, 助教 (30782221)
• Co-Investigator(Kenkyū-buntansha): 昆 泰寛 北海道大学, 獣医学研究院, 教授 (10178402) ; 市居 修 北海道大学, 獣医学研究院, 准教授 (60547769)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: lung injury / MFALCs / streptozoticin / Lung asthma / diabetes / Bleomycin / autoimmune diseases / immune cells

Outline of Final Research Achievements

The pathological Alternations of mediastinal fat-associated lymphoid clusters (MFALCs) and lung injury following metabolic disorder (diabetes induction) (Elewa et al. 2021, Microscopy and microanalysis) and asthma induction (Elewa et al. 2021, Int. J. Mol. Sci.) were revealed. Furthermore, we could clarify the impact of either dexamethasone or bleomycin on the degree of lung injury and MFALCs development in autoimmune-induced lung lesions. From the data analysis of these experiments, I could publish in three high-impact Journals (Elewa et al. 2021, Front. Immunol.; Elewa et al. 2022, Microscopy and Microanalysis; Elewa et al. 2022, Int. J. Mol. Sci.). Also, through collaborative research with other researchers within my lab and other institutions inside Japan and outside Japan, and from this collaboration, I could publish the data in 30 high impacted Journals.

Free Research Field

Immunity and lung lesions

Academic Significance and Societal Importance of the Research Achievements

We clarified the impact of MFALCs targeting in the revealing of lung injury in several mice models.Therefore, this study could open the bright future of human respiratory diseases by introducing innovative therapeutic strategies for respiratory diseases